Sort   by:  
 Page size 
TranscriptomicsADAR1 regulates the resistance of melanoma cells to T cells via miR-222 and ICAM1
The blossom of immunotherapy in melanoma highlights the need to delineate mechanisms of immune resistance. Recently, we have demonstrated that the RNA editing protein, adenosine deaminase acting on RNA-1 (ADAR1) is down-regulated during metastatic transition of melanoma, which enhances melanoma cell...
ORGANISM(S): Homo sapiens 
2015-12-31 | E-GEOD-67496 | biostudies-arrayexpress
GenomicsBiopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1-refractory melanoma
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1-refractory melanoma
PRJNA1263048 | ENA
GenomicsBiopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1-refractory melanoma
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1-refractory melanoma
PRJNA1263050 | ENA
GenomicsImmunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160)
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160)
PRJNA668116 | ENA
GenomicsRNA-sequencing analysis of CD4 T cells following ipilimumab therapy
RNA-sequencing analysis of CD4 T cells following ipilimumab therapy
PRJNA472360 | ENA
TranscriptomicsRNA-sequencing analysis of CD4 T cells following ipilimumab therapy
We sorted CD4 T cells from patients with metastatic melanoma at baseline and after three doses of ipilimumab.
ORGANISM(S): Homo sapiens 
2018-05-22 | GSE114716 | GEO
TranscriptomicsImmunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160)
Pre-treatment (PT) and On-Treatment (C3D8) biopsy samples from patients on the Phase I trial of Ipilimumab and Evofosfamide (NCT03098160) were analyzed by RNA sequencing.
ORGANISM(S): Homo sapiens 
2021-06-09 | GSE159237 | GEO
ModelsLiu2019 - Logistic Regression models to predict intrinsic resistance to anti-PD1 ICB in Ipilimumab treated and Ipilimumab naive patients with metastatic melanoma.
In this comprehensive study, the authors have developed concise models integrating clinical, genomic and transcriptomic features to predict intrinsic resistance to anti-PD1 Immune Checkpoint Blockade (ICB) treatment in individual tumors. It's important to note that their validation was performed in ...
2023-11-17 | MODEL2310150001 | BioModels
Machine Learning Model FAIR-AIML 
UnknownNivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Not available
S-EPMC5744258 | biostudies-literature
TranscriptomicsMechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease
The ETCTN 10026 study tested decitabine and ipilimumab for transplant-naive advanced myelodysplastic syndrome/acute myeloid leukemia and relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Using single cell RNA sequencing, determinants of response (higher T/NK t...
ORGANISM(S): Homo sapiens 
2023-10-31 | GSE223844 | GEO
Sort   by:  
 Page size